查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1933366

全球重組白蛋白市場：市場規模、佔有率、成長率、產業分析、依類型、應用和地區劃分的考量、未來預測（2026-2034）

Recombinant Albumin Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 167 Pages | 商品交期: 請詢問到貨日

價格

重組白蛋白市場成長因子

預計2025年全球重組白蛋白市場規模將達到1506.7億美元，2026年將成長至1592.6億美元，最終在2034年達到2600.4億美元，預測期內複合年增長率（CAGR）為6.05%。亞太地區將引領市場，預計2025年將佔49.28%的市場佔有率，這主要得益於慢性腎臟病率的上升、醫療保健支出的增加以及主要市場參與者之間的策略聯盟。重組白蛋白是一種主要的血漿蛋白，它為人類來源的白蛋白提供了一種安全且可規模化生產的替代方案，可應用於藥物遞送、診斷、細胞培養補充劑等領域。

InVitria、富士膠片和光純藥株式會社以及賽多利斯股份公司等主要公司正在擴大其地域覆蓋範圍，並加大研發投入，以鞏固其市場主導地位。策略合作和創新產品的推出進一步推動了市場成長，實現了適用於先進療法的無病毒重組白蛋白的大規模生產。

市場動態

成長驅動因素：重組白蛋白在細胞和基因治療領域應用的不斷擴展是關鍵的成長驅動因素。它能夠穩定敏感的治療分子，提高細胞活力，並保護它們免受聚集和降解。例如，Albumedix 於 2021 年 2 月與 CGT Catapult 合作，共同研究用於先進治療應用的白蛋白解決方案，這充分體現了其在該領域的重要性。

限制因素：供應限制對市場擴張構成挑戰。重組白蛋白的生產需要複雜的表達系統、符合GMP規範以及昂貴的純化技術，導致產量低、生產成本高。例如，三菱化學集團公司由於供應不穩定，於2022年7月停止了重組人血清的生產。

機會：先進藥物遞送系統（例如奈米白蛋白結合（nab）技術）的研發正在創造豐厚的市場機會。 nab技術可以提高低溶解度、高毒性藥物的傳遞效率並減少副作用。例如，山德士公司於2024年10月推出了用於治療轉移性乳癌的紫杉醇白蛋白結合仿製藥。

挑戰：重組白蛋白的高成本限制了其廣泛應用。 Optivmin 20 等產品的定價為每 100 毫升 1,660 美元，這反映了其複雜的生產和純化工藝，限制了其廣泛應用。

市場趨勢

主要公司擴大產能是關鍵趨勢。細胞和基因治療領域對 GMP 級重組白蛋白的需求不斷增長，推動了生產擴張方面的投資。例如，煙台普吉藥業科技有限公司於 2025 年 3 月宣布了重組白蛋白生產擴建項目，顯示市場成長勢頭強勁。

細分市場分析

依劑型劃分：溶液劑型因其污染風險低、即用型配方和穩定性而佔主導地位。 Invitria 於 2025 年 2 月推出了 Optibumin 25 溶液，為細胞和基因治療領域的生物製造提供了安全的替代方案。

依應用領域劃分：2024年，治療領域佔最大的市場佔有率。重組白蛋白因其良好的生物相容性和穩定性，在治療領域作為賦形劑和活性成分發揮著至關重要的作用。例如，2023年3月，Albumedix與Heartseed合作，開始為心臟再生細胞療法供應Recombumin。

依最終用戶劃分：製藥和生技產業是主要的最終用戶，他們利用策略聯盟、擴大生產規模和建立商業化合作夥伴關係。 2024年6月，Dyadic International與PHB達成合作，共同推動重組白蛋白的商業化，計畫於2025年上市。

區域展望

亞太地區：受慢性病高發生率、醫療成本上升以及策略聯盟的推動，預計到2025年，亞太市場規模將達到742.5億美元。

北美地區：得益於強大的生物製藥研發基礎和符合GMP標準的生產設施，預計到2025年，北美市場將穩步增長至4450萬美元，複合年增長率（CAGR）為5.08%。

歐洲：受先進研究和治療應用需求的推動，預計到 2025 年，市場規模將達到 2,400 萬美元，複合年增長率 (CAGR) 為 4.02%。

拉丁美洲、中東和非洲：預期成長溫和，到 2025 年，拉丁美洲市場規模將達到 610 萬美元，這主要得益於再生醫學的普及和重組白蛋白使用量的增加。

目錄

第一章：引言

第二章：摘要整理

第三章：市場動態

  • 市場驅動因素
  • 市場限制因素
  • 市場機遇
  • 市場趨勢

第四章：關鍵考慮因素

  • 市場技術進步
  • 主要國家的監管狀況（2025 年）
  • 主要公司產品線分析
  • 關鍵趨勢：併購、業務合作等

第五章：全球重組白蛋白市場分析：洞察與預測（2021-2034）

  • 市場分析、洞察與預測：依劑型劃分
    • 粉劑
    • 溶液
  • 市場分析、洞察與預測：依應用劃分
    • 治療
    • 診斷
    • 研究
  • 市場分析、洞察與預測：依最終用戶劃分
    • 醫院和診所
    • 製藥和生物技術產業
    • 研究機構
  • 市場分析、洞察與預測：依地區劃分
    • 北美
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲

第六章 北美重組白蛋白市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 美國
    • 加拿大

第七章 歐洲重組白蛋白市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 斯堪的納維亞
    • 歐洲其他地區

第八章 亞太地區重組白蛋白市場分析：洞察與預測（2021-2034）

  • 依國家/地區
    • 中國
    • 日本
    • 印度
    • 澳大利亞
    • 東南亞
    • 亞太其他地區

第九章：拉丁美洲重組白蛋白市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地區

第十章：中東與非洲重組白蛋白市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 海灣合作委員會（GCC）國家
    • 南非
    • 中東其他地區非洲

第11章 競爭分析

  • 世界市場佔有率分析(2025年)
  • 企業簡介
  • InVitria
  • FUJIFILM Wako Pure Chemical Corporation
  • Orion Corporation
  • Sartorius AG
  • Thermo Fisher Scientific Inc.
  • Merck KGaA
Product Code: FBI113883

Growth Factors of recombinant albumin Market

The global recombinant albumin market was valued at USD 150.67 billion in 2025 and is projected to grow to USD 159.26 billion in 2026, eventually reaching USD 260.04 billion by 2034, exhibiting a CAGR of 6.05% during the forecast period. Asia Pacific dominated the market in 2025 with a 49.28% share, driven by the increasing prevalence of chronic kidney diseases, rising healthcare expenditure, and strategic collaborations between major market players. Recombinant albumin, a key plasma protein, serves as a safer and scalable alternative to human-derived albumin, providing applications in drug delivery, diagnostics, and as a cell culture supplement.

Key players such as InVitria, FUJIFILM Wako Pure Chemical Corporation, and Sartorius AG are expanding their geographic presence and investing in research and development (R&D) to strengthen their market dominance. Strategic collaborations and innovative product launches further support the growth of the market, enabling large-scale production of virus-free recombinant albumin suitable for advanced therapeutics.

Market Dynamics

Drivers: The increasing application of recombinant albumin in cell and gene therapy is a major growth driver. It stabilizes sensitive therapeutic molecules, improves cell viability, and protects against aggregation or degradation. For instance, Albumedix collaborated with CGT Catapult in February 2021 to explore albumin-based solutions for advanced therapy applications, demonstrating its critical role in this sector.

Restraints: Supply limitations pose a challenge for market expansion. Manufacturing recombinant albumin requires advanced expression systems, GMP compliance, and costly purification technologies. These factors lead to low yields and high production costs. For example, Mitsubishi Chemical Group Corporation terminated its recombinant human serum production in July 2022 due to supply instability.

Opportunities: Research and development in advanced drug delivery systems, such as nanoparticle albumin-bound (nab) technology, is creating lucrative opportunities. Nab-technology improves delivery of low-solubility and high-toxicity drugs with fewer side effects. For instance, Sandoz launched a generic paclitaxel albumin-bound formulation in October 2024 for metastatic breast cancer therapy.

Challenges: The high cost of recombinant albumin limits adoption. Products like Optibumin 20 are priced at USD 1,660 for 100 mL, reflecting the complex production and purification processes involved, which hampers widespread usage.

Market Trends

An important trend is the expansion of manufacturing capacity by key players. Increasing demand for GMP-grade recombinant albumin in cell and gene therapies has driven investments in production scale-up. For example, Yantai Projiji Pharmaceutical Technology Co., Ltd. announced a recombinant albumin expansion project in March 2025, demonstrating market growth momentum.

Segmentation Analysis

By Dosage Form: The solution segment dominates due to lower contamination risk, ready-to-use formulations, and consistency. InVitria launched Optibumin 25 solution in February 2025, offering a safe alternative for biomanufacturing in cell and gene therapy.

By Application: The therapeutic segment captured the largest share in 2024. Recombinant albumin is essential as an excipient and active component in therapies due to its biocompatibility and stability. For example, Albumedix collaborated with Heartseed in March 2023 to supply Recombumin for cardiac remuscularization cell therapy.

By End-User: Pharmaceutical and biotechnology industries dominate as end-users, leveraging strategic collaborations, expanded manufacturing, and commercialization partnerships. In June 2024, Dyadic International partnered with PHB to commercialize recombinant albumin, with launches expected in 2025.

Regional Outlook

Asia Pacific: Dominated the market in 2025 with USD 74.25 billion, driven by chronic disease prevalence, rising healthcare expenditure, and strategic collaborations.

North America: Expected steady growth at a 5.08% CAGR, with USD 44.5 million in 2025, driven by a strong biopharma R&D base and GMP-compliant manufacturing facilities.

Europe: Projected growth at 4.02% CAGR, reaching USD 24.0 million in 2025, supported by advanced research and demand in therapeutic applications.

Latin America & Middle East & Africa: Moderate growth is expected, with Latin America reaching USD 6.1 million in 2025, aided by regenerative medicine adoption and increasing recombinant albumin usage.

Competitive Landscape

The market is concentrated, dominated by Sartorius AG, FUJIFILM Wako Pure Chemical Corporation, and InVitria. Their strong global presence, product portfolios, and strategic collaborations reinforce market leadership. Other key players include Thermo Fisher Scientific, Merck KGaA, and Orion Corporation. Notable developments include:

  • August 2023: Dyadic International announced positive testing results for animal-free recombinant albumin.
  • August 2022: Sartorius AG acquired Albumedix for USD 449.13 million.
  • July 2025: Wuhan Healthgen Biotechnology received approval for rice-derived recombinant human albumin injection in China.

Conclusion

The global recombinant albumin market is expected to grow from USD 150.67 billion in 2025 to USD 159.26 billion in 2026, reaching USD 260.04 billion by 2034 at a CAGR of 6.05%. Growth is driven by its widespread applications in therapeutics, cell and gene therapy, and advanced biologics manufacturing. Asia Pacific leads the market due to rising chronic disease prevalence and strategic collaborations. Despite challenges like high costs and supply limitations, R&D investments, manufacturing expansion, and drug delivery innovations are anticipated to drive significant market growth, making it a lucrative opportunity for major players and new entrants alike.

Segmentation By Dosage Form

  • Powder
  • Solution

By Application

  • Therapeutics
  • Diagnostics
  • Research

By End User

  • Hospital & Clinics
  • Pharmaceutical & Biotechnology Industry
  • Research Institutes

By Geography

  • North America (By Dosage Form, Application, End User, and Country)
    • U.S.
    • Canada
  • Europe (By Dosage Form, Application, End User, and Country/Sub-region)
    • Germany
    • U.K.
    • France
    • Spain
    • Italy
    • Scandinavia
    • Rest of Europe
  • Asia Pacific (By Dosage Form, Application, End User, and Country/Sub-region)
    • China
    • Japan
    • India
    • Australia
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America (By Dosage Form, Application, End User, and Country/Sub-region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Dosage Form, Application, End User, and Country/Sub-region)
    • GCC
    • South Africa
    • Rest of the Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Technological Advancements in the Market
  • 4.2. Regulatory Scenario by Key Countries/ Region, 2025
  • 4.3. Pipeline Analysis, By Key Players
  • 4.4. Key Industry Developments- Mergers, Acquisitions, Partnerships, etc.

5. Global Recombinant Albumin Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Dosage Form
    • 5.1.1. Powder
    • 5.1.2. Solutions
  • 5.2. Market Analysis, Insights and Forecast - By Application
    • 5.2.1. Therapeutics
    • 5.2.2. Diagnostics
    • 5.2.3. Research
  • 5.3. Market Analysis, Insights and Forecast - By End User
    • 5.3.1. Hospital & Clinics
    • 5.3.2. Pharmaceutical & Biotechnology Industry
    • 5.3.3. Research Institutes
  • 5.4. Market Analysis, Insights and Forecast - Region
    • 5.4.1. North America
    • 5.4.2. Europe
    • 5.4.3. Asia Pacific
    • 5.4.4. Latin America
    • 5.4.5. Middle East & Africa

6. North America Recombinant Albumin Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Dosage Form
    • 6.1.1. Powder
    • 6.1.2. Solution
  • 6.2. Market Analysis, Insights and Forecast - By Application
    • 6.2.1. Therapeutics
    • 6.2.2. Diagnostics
    • 6.2.3. Research
  • 6.3. Market Analysis, Insights and Forecast - By End User
    • 6.3.1. Hospital & Clinics
    • 6.3.2. Pharmaceutical & Biotechnology Industry
    • 6.3.3. Research Institutes
  • 6.4. Market Analysis, Insights and Forecast - By Country
    • 6.4.1. U.S.
    • 6.4.2. Canada

7. Europe Recombinant Albumin Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Dosage Form
    • 7.1.1. Powder
    • 7.1.2. Solution
  • 7.2. Market Analysis, Insights and Forecast - By Application
    • 7.2.1. Therapeutics
    • 7.2.2. Diagnostics
    • 7.2.3. Research
  • 7.3. Market Analysis, Insights and Forecast - By End User
    • 7.3.1. Hospital & Clinics
    • 7.3.2. Pharmaceutical & Biotechnology Industry
    • 7.3.3. Research Institutes
  • 7.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 7.4.1. Germany
    • 7.4.2. U.K.
    • 7.4.3. France
    • 7.4.4. Italy
    • 7.4.5. Spain
    • 7.4.6. Scandinavia
    • 7.4.7. Rest of Europe

8. Asia Pacific Recombinant Albumin Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Dosage Form
    • 8.1.1. Powder
    • 8.1.2. Solution
  • 8.2. Market Analysis, Insights and Forecast - By Application
    • 8.2.1. Therapeutics
    • 8.2.2. Diagnostics
    • 8.2.3. Research
  • 8.3. Market Analysis, Insights and Forecast - By End User
    • 8.3.1. Hospital & Clinics
    • 8.3.2. Pharmaceutical & Biotechnology Industry
    • 8.3.3. Research Institutes
  • 8.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 8.4.1. China
    • 8.4.2. Japan
    • 8.4.3. India
    • 8.4.4. Australia
    • 8.4.5. Southeast Asia
    • 8.4.6. Rest of Asia Pacific

9. Latin America Recombinant Albumin Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Dosage Form
    • 9.1.1. Powder
    • 9.1.2. Solution
  • 9.2. Market Analysis, Insights and Forecast - By Application
    • 9.2.1. Therapeutics
    • 9.2.2. Diagnostics
    • 9.2.3. Research
  • 9.3. Market Analysis, Insights and Forecast - By End User
    • 9.3.1. Hospital & Clinics
    • 9.3.2. Pharmaceutical & Biotechnology Industry
    • 9.3.3. Research Institutes
  • 9.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 9.4.1. Brazil
    • 9.4.2. Mexico
    • 9.4.3. Rest of Latin America

10. Middle East & Africa Recombinant Albumin Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Market Analysis, Insights and Forecast - By Dosage Form
    • 10.1.1. Powder
    • 10.1.2. Solution
  • 10.2. Market Analysis, Insights and Forecast - By Application
    • 10.2.1. Therapeutics
    • 10.2.2. Diagnostics
    • 10.2.3. Research
  • 10.3. Market Analysis, Insights and Forecast - By End User
    • 10.3.1. Hospital & Clinics
    • 10.3.2. Pharmaceutical & Biotechnology Industry
    • 10.3.3. Research Institutes
  • 10.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 10.4.1. GCC
    • 10.4.2. South Africa
    • 10.4.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2025)
  • 11.2. Company Profiles (Overview, Product, SWOT analysis, Recent developments, strategies, financials (based on availability))
    • 11.2.1. InVitria
    • 11.2.2. FUJIFILM Wako Pure Chemical Corporation
    • 11.2.3. Orion Corporation
    • 11.2.4. Sartorius AG
    • 11.2.5. Thermo Fisher Scientific Inc.
    • 11.2.6. Merck KGaA

List of Tables

  • Table 1: Global Recombinant Albumin Market Revenue (USD million) Forecast, by Dosage Form, 2021-2034
  • Table 2: Global Recombinant Albumin Market Revenue (USD million) Forecast, by Application, 2021-2034
  • Table 3: Global Recombinant Albumin Market Revenue (USD million) Forecast, by End User, 2021-2034
  • Table 4: Global Recombinant Albumin Market Revenue (USD million) Forecast, by Region, 2021-2034
  • Table 5: North America Recombinant Albumin Market Revenue (USD million) Forecast, by Dosage Form, 2021-2034
  • Table 6: North America Recombinant Albumin Market Revenue (USD million) Forecast, by Application, 2021-2034
  • Table 7: North America Recombinant Albumin Market Revenue (USD million) Forecast, by End User, 2021-2034
  • Table 8: North America Recombinant Albumin Market Revenue (USD million) Forecast, By Country, 2021-2034
  • Table 9: Europe Recombinant Albumin Market Revenue (USD million) Forecast, by Dosage Form, 2021-2034
  • Table 10: Europe Recombinant Albumin Market Revenue (USD million) Forecast, by Application, 2021-2034
  • Table 11: Europe Recombinant Albumin Market Revenue (USD million) Forecast, by End User, 2021-2034
  • Table 12: Europe Recombinant Albumin Market Revenue (USD million) Forecast, By Country/ Sub-region, 2021-2034
  • Table 13: Asia Pacific Recombinant Albumin Market Revenue (USD million) Forecast, by Dosage Form, 2021-2034
  • Table 14: Asia Pacific Recombinant Albumin Market Revenue (USD million) Forecast, by Application, 2021-2034
  • Table 15: Asia Pacific Recombinant Albumin Market Revenue (USD million) Forecast, by End User, 2021-2034
  • Table 16: Asia Pacific Recombinant Albumin Market Revenue (USD million) Forecast, By Country/ Sub-region, 2021-2034
  • Table 17: Latin America Recombinant Albumin Market Revenue (USD million) Forecast, by Dosage Form, 2021-2034
  • Table 18: Latin America Recombinant Albumin Market Revenue (USD million) Forecast, by Application, 2021-2034
  • Table 19: Latin America Recombinant Albumin Market Revenue (USD million) Forecast, by End User, 2021-2034
  • Table 20: Latin America Recombinant Albumin Market Revenue (USD million) Forecast, By Country/ Sub-region, 2021-2034
  • Table 21: Middle East & Africa Recombinant Albumin Market Revenue (USD million) Forecast, by Dosage Form, 2021-2034
  • Table 22: Middle East & Africa Recombinant Albumin Market Revenue (USD million) Forecast, by Application, 2021-2034
  • Table 23: Middle East & Africa Recombinant Albumin Market Revenue (USD million) Forecast, by End User, 2021-2034
  • Table 24: Middle East & Africa Recombinant Albumin Market Revenue (USD million) Forecast, By Country/ Sub-region, 2021-2034

List of Figures

  • Figure 1: Global Recombinant Albumin Market Revenue Breakdown (USD million, %) by Region, 2025 & 2034
  • Figure 2: Global Recombinant Albumin Market Value Share (%), by Dosage Form, 2025 & 2034
  • Figure 3: Global Recombinant Albumin Market Value Share (%), by Application, 2025 & 2034
  • Figure 4: Global Recombinant Albumin Market Value Share (%), by End User, 2025 & 2034
  • Figure 5: Global Recombinant Albumin Market Value Share (%), by Region, 2025 & 2034
  • Figure 6: North America Recombinant Albumin Market Value (USD million), by Dosage Form, 2025 & 2034
  • Figure 7: North America Recombinant Albumin Market Value Share (%), by Dosage Form, 2025
  • Figure 8: North America Recombinant Albumin Market Value (USD million), by Application, 2025 & 2034
  • Figure 9: North America Recombinant Albumin Market Value Share (%), by Application, 2025
  • Figure 10: North America Recombinant Albumin Market Value (USD million), by End User, 2025 & 2034
  • Figure 11: North America Recombinant Albumin Market Value Share (%), by End User, 2025
  • Figure 12: North America Recombinant Albumin Market Value (USD million), By Country, 2025 & 2034
  • Figure 13: North America Recombinant Albumin Market Value Share (%), By Country, 2025
  • Figure 14: Europe Recombinant Albumin Market Value (USD million), by Dosage Form, 2025 & 2034
  • Figure 15: Europe Recombinant Albumin Market Value Share (%), by Dosage Form, 2025
  • Figure 16: Europe Recombinant Albumin Market Value (USD million), by Application, 2025 & 2034
  • Figure 17: Europe Recombinant Albumin Market Value Share (%), by Application, 2025
  • Figure 18: Europe Recombinant Albumin Market Value (USD million), by End User, 2025 & 2034
  • Figure 19: Europe Recombinant Albumin Market Value Share (%), by End User, 2025
  • Figure 20: Europe Recombinant Albumin Market Value (USD million), By Country/ Sub-region, 2025 & 2034
  • Figure 21: Europe Recombinant Albumin Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 22: Asia Pacific Recombinant Albumin Market Value (USD million), by Dosage Form, 2025 & 2034
  • Figure 23: Asia Pacific Recombinant Albumin Market Value Share (%), by Dosage Form, 2025
  • Figure 24: Asia Pacific Recombinant Albumin Market Value (USD million), by Application, 2025 & 2034
  • Figure 25: Asia Pacific Recombinant Albumin Market Value Share (%), by Application, 2025
  • Figure 26: Asia Pacific Recombinant Albumin Market Value (USD million), by End User, 2025 & 2034
  • Figure 27: Asia Pacific Recombinant Albumin Market Value Share (%), by End User, 2025
  • Figure 28: Asia Pacific Recombinant Albumin Market Value (USD million), By Country/ Sub-region, 2025 & 2034
  • Figure 29: Asia Pacific Recombinant Albumin Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 30: Latin America Recombinant Albumin Market Value (USD million), by Dosage Form, 2025 & 2034
  • Figure 31: Latin America Recombinant Albumin Market Value Share (%), by Dosage Form, 2025
  • Figure 32: Latin America Recombinant Albumin Market Value (USD million), by Application, 2025 & 2034
  • Figure 33: Latin America Recombinant Albumin Market Value Share (%), by Application, 2025
  • Figure 34: Latin America Recombinant Albumin Market Value (USD million), by End User, 2025 & 2034
  • Figure 35: Latin America Recombinant Albumin Market Value Share (%), by End User, 2025
  • Figure 36: Latin America Recombinant Albumin Market Value (USD million), By Country/ Sub-region, 2025 & 2034
  • Figure 37: Latin America Recombinant Albumin Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 38: Middle East & Africa Recombinant Albumin Market Value (USD million), by Dosage Form, 2025 & 2034
  • Figure 39: Middle East & Africa Recombinant Albumin Market Value Share (%), by Dosage Form, 2025
  • Figure 40: Middle East & Africa Recombinant Albumin Market Value (USD million), by Application, 2025 & 2034
  • Figure 41: Middle East & Africa Recombinant Albumin Market Value Share (%), by Application, 2025
  • Figure 42: Middle East & Africa Recombinant Albumin Market Value (USD million), by End User, 2025 & 2034
  • Figure 43: Middle East & Africa Recombinant Albumin Market Value Share (%), by End User, 2025
  • Figure 44: Middle East & Africa Recombinant Albumin Market Value (USD million), By Country/ Sub-region, 2025 & 2034
  • Figure 45: Middle East & Africa Recombinant Albumin Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 46: Global Recombinant Albumin Market Share (%), By Company, 2025